Scalper1 News
Big cap biotech Celgene (CELG) provided a preliminary fourth-quarter earnings report Monday that topped estimates but warned of foreign exchange currency impacts for the year ahead. Results were presented prior to its presentation early Monday at the annual JPMorgan Healthcare Conference in San Francisco. For the fourth quarter Celgene forecast net product sales to be approximately $2.05 billion, including about $25 million of negative Scalper1 News
Scalper1 News